Published in Medical Letter on the CDC and FDA, March 25th, 2007
The Food and Drug Administration (FDA) issued the approval for Tekturna as the first in a new class of drugs called direct renin inhibitors. A once-daily oral therapy, Tekturna acts by targeting renin -- an enzyme responsible for triggering a process that can contribute to high blood pressure. This condition is a leading contributor to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA